[go: up one dir, main page]

WO2002090325A3 - Benzazepinones, antagonistes de recepteur d'integrine alpha v - Google Patents

Benzazepinones, antagonistes de recepteur d'integrine alpha v Download PDF

Info

Publication number
WO2002090325A3
WO2002090325A3 PCT/US2002/013457 US0213457W WO02090325A3 WO 2002090325 A3 WO2002090325 A3 WO 2002090325A3 US 0213457 W US0213457 W US 0213457W WO 02090325 A3 WO02090325 A3 WO 02090325A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
integrin receptor
benzazepinone
alpha
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/013457
Other languages
English (en)
Other versions
WO2002090325A2 (fr
Inventor
Robert S Meissner
Paul J Coleman
Mark E Duggan
George D Hartman
John H Hutchinson
Jiabing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to CA002445679A priority Critical patent/CA2445679A1/fr
Priority to JP2002587405A priority patent/JP2004528373A/ja
Priority to EP02725848A priority patent/EP1387688A2/fr
Priority to US10/475,697 priority patent/US7109191B2/en
Publication of WO2002090325A2 publication Critical patent/WO2002090325A2/fr
Publication of WO2002090325A3 publication Critical patent/WO2002090325A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des dérivés benzazépinone, leur synthèse et leur utilisation en tant qu'antagonistes de récepteur d'intégrine αξ. Les composés de l'invention sont plus particulièrement des antagonistes des récepteur d'intégrine αξβ3 et αξβ5 et sont donc utiles afin d'inhiber la résorption osseuse, de traiter et/ou de prévenir l'ostéoporose, et d'inhiber la resténose vasculaire, la rétinopathie diabétique, la dégénérescence maculaire, l'angiogénèse, l'athérosclérose, l'arthrite inflammatoire, le cancer et la croissance de métastase.
PCT/US2002/013457 2001-05-03 2002-04-29 Benzazepinones, antagonistes de recepteur d'integrine alpha v Ceased WO2002090325A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002445679A CA2445679A1 (fr) 2001-05-03 2002-04-29 Benzazepinones, antagonistes de recepteur d'integrine alpha v
JP2002587405A JP2004528373A (ja) 2001-05-03 2002-04-29 ベンズアゼピノンαＶインテグリン受容体拮抗物質
EP02725848A EP1387688A2 (fr) 2001-05-03 2002-04-29 Benzazepinones, antagonistes de recepteur d'integrine alpha v
US10/475,697 US7109191B2 (en) 2001-05-03 2002-04-29 Benzazepinone alpha vintegrin receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28857801P 2001-05-03 2001-05-03
US60/288,578 2001-05-03

Publications (2)

Publication Number Publication Date
WO2002090325A2 WO2002090325A2 (fr) 2002-11-14
WO2002090325A3 true WO2002090325A3 (fr) 2003-02-27

Family

ID=23107720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/013457 Ceased WO2002090325A2 (fr) 2001-05-03 2002-04-29 Benzazepinones, antagonistes de recepteur d'integrine alpha v

Country Status (5)

Country Link
US (1) US7109191B2 (fr)
EP (1) EP1387688A2 (fr)
JP (1) JP2004528373A (fr)
CA (1) CA2445679A1 (fr)
WO (1) WO2002090325A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7752266B2 (en) 2001-10-11 2010-07-06 Ebay Inc. System and method to facilitate translation of communications between entities over a network
US8078505B2 (en) 2002-06-10 2011-12-13 Ebay Inc. Method and system for automatically updating a seller application utilized in a network-based transaction facility
BR0318454A (pt) 2003-08-08 2006-09-12 Abgenix Inc anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US8639782B2 (en) 2006-08-23 2014-01-28 Ebay, Inc. Method and system for sharing metadata between interfaces
JP5098011B2 (ja) * 2006-11-20 2012-12-12 国立大学法人山口大学 創傷治癒促進剤
KR101588469B1 (ko) 2007-11-16 2016-01-25 우베 고산 가부시키가이샤 벤즈아제피논 화합물
CA2757396A1 (fr) * 2009-03-30 2010-10-07 Ube Industries, Ltd. Composition medicale pour le traitement ou la prophylaxie de maladies des yeux
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
SI3929196T1 (sl) 2013-09-24 2023-11-30 Fujifilm Corporation Farmacevtska sestava spojine, ki vsebuje dušik ali njegovo sol ali njegov kovinski kompleks
EP4159727A1 (fr) 2017-02-28 2023-04-05 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
EP4147698A1 (fr) 2017-02-28 2023-03-15 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
TW202035400A (zh) 2018-08-29 2020-10-01 美商莫菲克醫療股份有限公司 抑制αvβ6整合素

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014192A1 (fr) * 1996-10-02 1998-04-09 Smithkline Beecham Corporation Antagonistes du recepteur de la vitronectine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125317A1 (en) * 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP1150965A4 (fr) 1999-02-03 2002-05-15 Merck & Co Inc Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
WO2000048603A1 (fr) 1999-02-17 2000-08-24 Merck & Co., Inc. DERIVES DE LA DIBENZO-AZEPINE EN TANT QU'ANTAGONISTES DU RECEPTEUR αV INTEGRINE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014192A1 (fr) * 1996-10-02 1998-04-09 Smithkline Beecham Corporation Antagonistes du recepteur de la vitronectine

Also Published As

Publication number Publication date
CA2445679A1 (fr) 2002-11-14
JP2004528373A (ja) 2004-09-16
US20040142919A1 (en) 2004-07-22
US7109191B2 (en) 2006-09-19
WO2002090325A2 (fr) 2002-11-14
EP1387688A2 (fr) 2004-02-11

Similar Documents

Publication Publication Date Title
WO2000072801A3 (fr) Antagonistes du recepteur de l'alpha v integrine
DE69720771D1 (en) Integrin antagonist
CA2277273A1 (fr) Antagonistes d'integrine
CA2315220A1 (fr) Antagonistes du recepteur de l'integrine
IL136314A0 (en) Integrin receptor antagonists
AU2450197A (en) Alphavbeta3 antagonists
DE69830806D1 (de) Integrinrezeptor antagonisten
WO2002090325A3 (fr) Benzazepinones, antagonistes de recepteur d'integrine alpha v
AU7793501A (en) Alpha v integrin receptor antagonists
WO2002022616A3 (fr) Antagonistes du recepteur des integrines alpha v
WO2002040505A3 (fr) Antagoniste du recepteur de l'integrine de la dibenzoxazepine alpha v
YU38300A (sh) Antagonisti integrinskog receptora
YU38200A (sh) Antagonisti integrinskog receptora

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002725848

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002256387

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10475697

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2445679

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002587405

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002725848

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002725848

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642